公开(公告)号：EP2341913B1

公开(公告)日：2014-11-19

申请号：EP09815064.2

申请日：2009-09-15

申请人： Saint Louis University ,  Auxagen, Inc.

发明人： HUANG, Jung, San ,  HUANG, Shuan, Shian

IPC分类号： A61P29/00 ,  A61P35/00 ,  A61P9/00 ,  A61P9/10 ,  A61P17/00 ,  A61K31/166 ,  A61K31/18 ,  A61K31/35 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/47 ,  A61K31/505 ,  A61K31/5415 ,  A61K31/724 ,  C07C245/04

CPC分类号： A61K31/166 ,  A61K31/18 ,  A61K31/35 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/47 ,  A61K31/505 ,  A61K31/5415 ,  A61K31/724 ,  C07C245/04 ,  C07C2601/16

公开(公告)号：EP2341913A1

公开(公告)日：2011-07-13

申请号：EP09815064.2

申请日：2009-09-15

申请人： Saint Louis University ,  Auxagen, Inc.

发明人： HUANG, Jung, San ,  HUANG, Shuan, Shian

IPC分类号： A61K31/7088 ,  A61K39/395

CPC分类号： A61K31/166 ,  A61K31/18 ,  A61K31/35 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/47 ,  A61K31/505 ,  A61K31/5415 ,  A61K31/724 ,  C07C245/04 ,  C07C2601/16

摘要： The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF- β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF- β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.

公开(公告)号：EP2192904B1

公开(公告)日：2016-08-17

申请号：EP08798785.5

申请日：2008-08-27

申请人： Auxagen, Inc. ,  St. Louis University

发明人： HUANG, Shuan, Shian ,  HUANG, Jung, San

IPC分类号： A61K31/56 ,  C07J9/00 ,  A61P17/02

CPC分类号： A61K31/56

公开(公告)号：EP2192904A1

公开(公告)日：2010-06-09

申请号：EP08798785.5

申请日：2008-08-27

申请人： Auxagen, Inc. ,  St. Louis University

发明人： HUANG, Shuan, Shian ,  HUANG, Jung, San

IPC分类号： A61K31/56 ,  C07J9/00

CPC分类号： A61K31/56

摘要： The present invention provides methods for inhibiting or blocking TGF-β activity in cells and/or tissues expressing TGF-β comprising, contacting cells and/or tissues expressing TGF-β with an amount of cholesterol or cholesterol derivative effective to inhibit the activity of TGF-β. The present invention further provides a method for treating a condition associated with overactivity of TGF-β or negative regulation in normal physiology by TGF-β in a subject in need of treatment, comprising contacting cells and/or tissue overexpressing TGF-β in the subject with an amount of cholesterol or cholesterol derivative effective to inhibit activity of TGF-β thereby treating the condition. In a preferred embodiment, the cholesterol derivative is oxidized 7-DHC.